
    
      Administration of the candidate vaccine or of the active control (Mencevax™ ACWY) will be
      done in an open manner. The study consists of a vaccination phase during which subjects
      receive one vaccine dose (GSK's MenACWY conjugate vaccine or Mencevax™ ACWY vaccine) and 3
      years of follow-up. There are in total 7 visits to the doctor: before and 2, 7 and 30 days
      after vaccination (vaccination phase) as well as 12, 24 and 36 months after vaccination
      (follow-up phase). 7 blood samples are taken: one at each visit.
    
  